Commentary: Digital health companies should stay away from FDA in 2021
Share It’s been quite a year: COVID-19, a change in administration and a year of transition for FDA digital health policy. In light of all the change and uncertainty, many digital health companies are struggling to decide upon a regulatory strategy for 2021. My advice? If at all possible, stay away from FDA. They have enough to do right now. The people I know at FDA have been working 12- and 15-hour days most of the year. They’ve been doing incredible work, both on the review side ...
Digital Health Center Radiological Health Good Housekeeping Seal Warning Letters Has Come Attention Letters
Source: mobihealthnews.com